Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H6O3 |
| Molecular Weight | 186.1635 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1OC2=C(C=C1)C=C3C=COC3=C2
InChI
InChIKey=ZCCUUQDIBDJBTK-UHFFFAOYSA-N
InChI=1S/C11H6O3/c12-11-2-1-7-5-8-3-4-13-9(8)6-10(7)14-11/h1-6H
Psoralen, the active ingredient of Fructus Psoraleae (FP) the dried ripe fruit of Psoralea corylifolia L., which is used in Chinese herbal medicine. Psoralen promotes chondrocyte proliferation by activating the Wnt/β-catenin signaling pathway and can play an important role in the treatment of osteoarthritis. Besides, this compound stimulates osteoblast proliferation through the activation of NF-κB and MAPK signaling and may be a viable therapeutic agent in the treatment of osteoporosis.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| PUVA-induced apoptosis involves mitochondrial dysfunction caused by the opening of the permeability transition pore. | 2002-07-03 |
|
| The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis. | 2002-07 |
|
| Minimum number of 2'-O-(2-aminoethyl) residues required for gene knockout activity by triple helix forming oligonucleotides. | 2002-06-18 |
|
| Computer modeling of three-dimensional structure of DNA-packaging RNA (pRNA) monomer, dimer, and hexamer of Phi29 DNA packaging motor. | 2002-06-07 |
|
| Mechanisms of growth inhibition in keratinocytes by mercurio-substituted 4',5'-dihydropsoralens. | 2002-06-01 |
|
| Binding affinities of commonly employed sensitizers of viral inactivation. | 2002-06 |
|
| Incidence and risk factors associated with a second squamous cell carcinoma or basal cell carcinoma in psoralen + ultraviolet a light-treated psoriasis patients. | 2002-06 |
|
| Synthesis, photobiological activity and photoreactivity of methyl-thieno-8-azacoumarins, novel bioisosters of psoralen. | 2002-05-06 |
|
| Molecular cloning and characterisation of three new ATP-binding cassette transporter genes from the wheat pathogen Mycosphaerella graminicola. | 2002-05-01 |
|
| p53 and Fas ligand are required for psoralen and UVA-induced apoptosis in mouse epidermal cells. | 2002-05 |
|
| Sustained remission of Sézary syndrome. | 2002-04-30 |
|
| Effects of storage conditions on furocoumarin levels in intact, chopped, or homogenized parsnips. | 2002-04-24 |
|
| Maintenance psoralen plus ultraviolet A therapy: does it have a role in the treatment of severe atopic eczema? | 2002-04 |
|
| Chalcones and other constituents of Dorstenia prorepens and Dorstenia zenkeri. | 2002-04 |
|
| Phototherapy utilization for psoriasis is declining in the United States. | 2002-04 |
|
| Treatment of disseminated granuloma annulare with fumaric acid esters. | 2002-03-19 |
|
| Simultaneous determination of furanocoumarins in infusions and decoctions from "Carapiá" (dorstenia species) by high-performance liquid chromatography. | 2002-03-13 |
|
| Synthesis and vasorelaxant activity of new coumarin and furocoumarin derivatives. | 2002-03-11 |
|
| Calcipotriol for erythema annulare centrifugum. | 2002-02 |
|
| Effects of the isoflavone 4',5,7-trihydroxyisoflavone (genistein) on psoralen plus ultraviolet A radiation (PUVA)-induced photodamage. | 2002-02 |
|
| Extracorporeal photopheresis and adjuvant aerosolized granulocyte-macrophage colony-stimulating factor for Sézary syndrome. | 2002-02 |
|
| The effects of vitamin E on the skin lipid peroxidation and the clinical improvement in vitiligo patients treated with PUVA. | 2002-01-26 |
|
| Contribution of XPF functional domains to the 5' and 3' incisions produced at the site of a psoralen interstrand cross-link. | 2002-01-22 |
|
| Cell-impermeant pyridinium derivatives of psoralens as inhibitors of keratinocyte growth. | 2002-01-01 |
|
| Simple and rapid determination of psoralens in topic solutions using liquid chromatography. | 2002-01-01 |
|
| Evaluation of synergism in the feeding deterrence of some furanocoumarins on Spodoptera littoralis. | 2002-01 |
|
| Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. | 2002 |
|
| S. cerevisiae has three pathways for DNA interstrand crosslink repair. | 2001-12-19 |
|
| Nucleosome positioning at the replication fork. | 2001-12-17 |
|
| Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis. | 2001-12 |
|
| Photosensitization and mutation induced in Escherichia coli and Saccharomyces cerevisiae strains by dorstenin, a psoralen analog isolated from Dorstenia bahiensis. | 2001-12 |
|
| Selective enhancement of gene transfer by steroid-mediated gene delivery. | 2001-12 |
|
| Induction of apoptosis, depletion of glutathione, and DNA damage by extracorporeal photochemotherapy and psoralen with exposure to UV light in vitro. | 2001-11-29 |
|
| Bullous lesions in Bazex syndrome and successful treatment with oral psoralen phototherapy. | 2001-11 |
|
| Narrowband UVB phototherapy for the treatment of psoriasis: a review and update. | 2001-11 |
|
| Bakuchiol: a hepatoprotective compound of Psoralea corylifolia on tacrine-induced cytotoxicity in Hep G2 cells. | 2001-11 |
|
| Replication-deficient vaccinia virus gene therpay vector: evaluation of exogenous gene expression mediated by PUV-inactivated virus in glioma cells. | 2001-10-17 |
|
| Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets. | 2001-10 |
|
| Prevention of transfusion-associated graft-versus-host disease by inactivation of T cells in platelet components. | 2001-10 |
|
| Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. | 2001-10 |
|
| Modified technique of autologous noncultured epidermal cell transplantation for repigmenting vitiligo: a pilot study. | 2001-10 |
|
| Vitiligo: a retrospective comparative analysis of treatment modalities in 500 patients. | 2001-09 |
|
| Association between Sézary T cell-activating factor, Chlamydia pneumoniae, and cutaneous T cell lymphoma. | 2001-09 |
|
| Apoptosis and cutaneous T cell lymphoma. | 2001-09 |
|
| Universal Linkage System: versatile nucleic acid labeling technique. | 2001-05 |
|
| Adhesion of MNC to extracellular matrix proteins following in vitro photochemotherapy. | 2001 |
|
| Photochemical mutagenesis: examples and toxicological relevance. | 2001 |
|
| Reducing the risk of blood transfusion. | 2001 |
|
| Calcipotriol ointment. A review of its use in the management of psoriasis. | 2001 |
|
| Cutaneous T-cell lymphoma in a cardiac transplant recipient. | 2001 |
Sample Use Guides
To evaluate the effect of psoralen (PSO) (10^(-7); 10^(-6) and 10^(-5) mol/L) on the Wnt/β-catenin signaling pathway in chondrocytes, RT-PCR and western blot analysis were performed to determine the expression levels of Wnt-4, Frizzled-2, β-catenin, cyclin D1 and GSK-3β in chondrocytes. Compared with the control group, PSO efficiently upregulated the mRNA expression of Wnt-4, Frizzled-2, β-catenin, cyclin D1 (P<0.01 or P<0.05), but downregulated the mRNA expression of GSK-3β (P<0.01 or P<0.05). Similarly, the protein levels, respectively, corresponded to the mRNA expression (P<0.01 or P<0.05)
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C582
Created by
admin on Mon Mar 31 21:32:38 GMT 2025 , Edited by admin on Mon Mar 31 21:32:38 GMT 2025
|
||
|
NCI_THESAURUS |
C2163
Created by
admin on Mon Mar 31 21:32:38 GMT 2025 , Edited by admin on Mon Mar 31 21:32:38 GMT 2025
|
||
|
NCI_THESAURUS |
C25760
Created by
admin on Mon Mar 31 21:32:38 GMT 2025 , Edited by admin on Mon Mar 31 21:32:38 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2103294
Created by
admin on Mon Mar 31 21:32:38 GMT 2025 , Edited by admin on Mon Mar 31 21:32:38 GMT 2025
|
PRIMARY | |||
|
404562
Created by
admin on Mon Mar 31 21:32:38 GMT 2025 , Edited by admin on Mon Mar 31 21:32:38 GMT 2025
|
PRIMARY | |||
|
m9307
Created by
admin on Mon Mar 31 21:32:38 GMT 2025 , Edited by admin on Mon Mar 31 21:32:38 GMT 2025
|
PRIMARY | Merck Index | ||
|
66-97-7
Created by
admin on Mon Mar 31 21:32:38 GMT 2025 , Edited by admin on Mon Mar 31 21:32:38 GMT 2025
|
PRIMARY | |||
|
D005363
Created by
admin on Mon Mar 31 21:32:38 GMT 2025 , Edited by admin on Mon Mar 31 21:32:38 GMT 2025
|
PRIMARY | |||
|
1581672
Created by
admin on Mon Mar 31 21:32:38 GMT 2025 , Edited by admin on Mon Mar 31 21:32:38 GMT 2025
|
PRIMARY | |||
|
KTZ7ZCN2EX
Created by
admin on Mon Mar 31 21:32:38 GMT 2025 , Edited by admin on Mon Mar 31 21:32:38 GMT 2025
|
PRIMARY | |||
|
100000151998
Created by
admin on Mon Mar 31 21:32:38 GMT 2025 , Edited by admin on Mon Mar 31 21:32:38 GMT 2025
|
PRIMARY | |||
|
6199
Created by
admin on Mon Mar 31 21:32:38 GMT 2025 , Edited by admin on Mon Mar 31 21:32:38 GMT 2025
|
PRIMARY | |||
|
psoralen
Created by
admin on Mon Mar 31 21:32:38 GMT 2025 , Edited by admin on Mon Mar 31 21:32:38 GMT 2025
|
PRIMARY | |||
|
3528
Created by
admin on Mon Mar 31 21:32:38 GMT 2025 , Edited by admin on Mon Mar 31 21:32:38 GMT 2025
|
PRIMARY | |||
|
PSORALEN
Created by
admin on Mon Mar 31 21:32:38 GMT 2025 , Edited by admin on Mon Mar 31 21:32:38 GMT 2025
|
PRIMARY | |||
|
27616
Created by
admin on Mon Mar 31 21:32:38 GMT 2025 , Edited by admin on Mon Mar 31 21:32:38 GMT 2025
|
PRIMARY | |||
|
SUB126483
Created by
admin on Mon Mar 31 21:32:38 GMT 2025 , Edited by admin on Mon Mar 31 21:32:38 GMT 2025
|
PRIMARY | |||
|
C2586
Created by
admin on Mon Mar 31 21:32:38 GMT 2025 , Edited by admin on Mon Mar 31 21:32:38 GMT 2025
|
PRIMARY | |||
|
DTXSID00216205
Created by
admin on Mon Mar 31 21:32:38 GMT 2025 , Edited by admin on Mon Mar 31 21:32:38 GMT 2025
|
PRIMARY | |||
|
200-639-7
Created by
admin on Mon Mar 31 21:32:38 GMT 2025 , Edited by admin on Mon Mar 31 21:32:38 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
